EUR 3.92
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 2.06 Million EUR | 192.14% |
2022 | -2.24 Million EUR | 51.23% |
2021 | -4.59 Million EUR | -19.7% |
2020 | -3.83 Million EUR | -567.44% |
2019 | -575.13 Thousand EUR | -199.2% |
2018 | 579.8 Thousand EUR | -23.08% |
2017 | 753.77 Thousand EUR | 8.94% |
2016 | 691.9 Thousand EUR | 81.31% |
2015 | 381.61 Thousand EUR | 51.67% |
2014 | 251.6 Thousand EUR | 44.91% |
2013 | 173.62 Thousand EUR | 139.48% |
2012 | -439.76 Thousand EUR | -222.35% |
2011 | 359.41 Thousand EUR | -49.63% |
2010 | 713.58 Thousand EUR | 89.58% |
2009 | 376.39 Thousand EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 697 Thousand EUR | 0.0% |
2023 FY | 2.06 Million EUR | 192.14% |
2023 Q2 | -898.09 Thousand EUR | 0.0% |
2023 Q4 | -7.13 Million EUR | 0.0% |
2022 FY | -2.24 Million EUR | 51.23% |
2022 Q4 | -640.91 Thousand EUR | 0.0% |
2022 Q2 | -1.6 Million EUR | 0.0% |
2021 Q4 | -1.99 Million EUR | 0.0% |
2021 FY | -4.59 Million EUR | -19.7% |
2021 Q2 | -2.59 Million EUR | 0.0% |
2020 Q2 | -2.55 Million EUR | 0.0% |
2020 Q4 | -1.28 Million EUR | 0.0% |
2020 FY | -3.83 Million EUR | -567.44% |
2019 Q2 | -950.72 Thousand EUR | 0.0% |
2019 Q4 | -1.63 Million EUR | 0.0% |
2019 FY | -575.13 Thousand EUR | -199.2% |
2018 Q2 | 447.97 Thousand EUR | 0.0% |
2018 FY | 579.8 Thousand EUR | -23.08% |
2018 Q4 | 131.82 Thousand EUR | 0.0% |
2017 Q2 | 316.14 Thousand EUR | 0.0% |
2017 FY | 753.77 Thousand EUR | 8.94% |
2017 Q4 | 394.62 Thousand EUR | 0.0% |
2016 Q4 | 507.15 Thousand EUR | 0.0% |
2016 Q2 | 184.75 Thousand EUR | 0.0% |
2016 FY | 691.9 Thousand EUR | 81.31% |
2015 Q2 | 317 Thousand EUR | 0.0% |
2015 Q4 | 64.61 Thousand EUR | 0.0% |
2015 FY | 381.61 Thousand EUR | 51.67% |
2014 Q4 | 147.13 Thousand EUR | 0.0% |
2014 FY | 251.6 Thousand EUR | 44.91% |
2014 Q2 | 104.46 Thousand EUR | 0.0% |
2013 Q2 | 34.05 Thousand EUR | 0.0% |
2013 Q4 | 139.57 Thousand EUR | 0.0% |
2013 FY | 173.62 Thousand EUR | 139.48% |
2012 Q3 | -92.8 Thousand EUR | 0.0% |
2012 Q1 | -92.8 Thousand EUR | 0.0% |
2012 Q4 | 60.34 Thousand EUR | 165.02% |
2012 FY | -439.76 Thousand EUR | -222.35% |
2012 Q2 | -92.8 Thousand EUR | 0.0% |
2011 Q3 | 183.04 Thousand EUR | 0.0% |
2011 FY | 359.41 Thousand EUR | -49.63% |
2011 Q4 | -92.8 Thousand EUR | -150.7% |
2011 Q2 | 183.04 Thousand EUR | 0.0% |
2011 Q1 | 183.04 Thousand EUR | 0.0% |
2010 Q1 | 213.57 Thousand EUR | 0.0% |
2010 Q4 | 183.04 Thousand EUR | -14.29% |
2010 FY | 713.58 Thousand EUR | 89.58% |
2010 Q3 | 213.57 Thousand EUR | 0.0% |
2010 Q2 | 213.57 Thousand EUR | 0.0% |
2009 FY | 376.39 Thousand EUR | 0.0% |
2009 Q1 | 49.03 Thousand EUR | 0.0% |
2009 Q4 | 213.57 Thousand EUR | 335.52% |
2009 Q3 | 49.03 Thousand EUR | 0.0% |
2009 Q2 | 49.03 Thousand EUR | 0.0% |
2008 Q4 | 49.03 Thousand EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.41 Million EUR | 160.53% |
ABIVAX Société Anonyme | -127.37 Million EUR | 101.621% |
Adocia SA | -17.62 Million EUR | 111.72% |
Aelis Farma SA | -6.46 Million EUR | 131.966% |
Biophytis S.A. | -14.33 Million EUR | 114.409% |
Advicenne S.A. | -6.45 Million EUR | 131.985% |
IntegraGen SA | -183.77 Thousand EUR | 1223.848% |
Medesis Pharma S.A. | -4.22 Million EUR | 148.833% |
Neovacs S.A. | -6.9 Million EUR | 129.899% |
NFL Biosciences SA | -4.43 Million EUR | 146.616% |
Plant Advanced Technologies SA | -778.23 Thousand EUR | 365.381% |
Quantum Genomics Société Anonyme | -3.13 Million EUR | 165.831% |
Sensorion SA | -22.31 Million EUR | 109.257% |
Theranexus Société Anonyme | -7.64 Million EUR | 127.02% |
TME Pharma N.V. | -5.62 Million EUR | 136.723% |
Valbiotis SA | -7.16 Million EUR | 128.845% |
TheraVet SA | -2.17 Million EUR | 194.951% |
Valerio Therapeutics Société anonyme | -20.28 Million EUR | 110.18% |
argenx SE | -417.15 Million EUR | 100.495% |
BioSenic S.A. | -7.04 Million EUR | 129.337% |
Celyad Oncology SA | -8.45 Million EUR | 124.421% |
DBV Technologies S.A. | -85.24 Million EUR | 102.423% |
Galapagos NV | -88.26 Million EUR | 102.34% |
Genfit S.A. | -26.58 Million EUR | 107.77% |
GeNeuro SA | -14.35 Million EUR | 114.385% |
Hyloris Pharmaceuticals SA | -15.99 Million EUR | 112.914% |
Innate Pharma S.A. | -12.66 Million EUR | 116.302% |
Inventiva S.A. | -102.7 Million EUR | 102.011% |
MaaT Pharma SA | -19.94 Million EUR | 110.356% |
MedinCell S.A. | -20.97 Million EUR | 109.846% |
Nanobiotix S.A. | -26.77 Million EUR | 107.712% |
Onward Medical N.V. | -35.46 Million EUR | 105.824% |
Oryzon Genomics S.A. | -4.54 Million EUR | 145.399% |
OSE Immunotherapeutics SA | -22.98 Million EUR | 108.985% |
Oxurion NV | -12.11 Million EUR | 117.054% |
Pharming Group N.V. | -4.87 Million EUR | 142.326% |
Poxel S.A. | -28.76 Million EUR | 107.18% |
GenSight Biologics S.A. | -29.69 Million EUR | 106.955% |
Transgene SA | -30.01 Million EUR | 106.882% |
Financière de Tubize SA | -2.14 Million EUR | 196.33% |
UCB SA | 604 Million EUR | 99.658% |
Valneva SE | -82.08 Million EUR | 102.516% |
Vivoryon Therapeutics N.V. | -28.83 Million EUR | 107.162% |